FDA approves pill for hot flashes in menopausal women

TherapeuticsMD announced Monday that its single-pill hormone therapy for menopausal hot flashes has been approved for marketing by the U.S. Food and Drug Administration.

The new drug, which combines estradiol (estrogen) and progesterone in an oral softgel capsule, has been named Bijuva, and is expected to be available in the United States by April or May, the Boca Raton, Fla., company said.

For , the approval means a new option for . Currently, who want bio-identical hormone therapy—molecularly identical to the hormones produced by a woman's body—have to take two pills.

For the company, it means further entrance into a multibillion-dollar market of menopausal health care for women.

Dr. James Liu, president of the North American Menopause Society and chairman of Obstetrics and Gynecology at University Hospitals Cleveland Medical Center, said this is the first FDA approval of a combination therapy "evaluated in a large, well-controlled, that has demonstrated both safety and efficacy for the treatment of moderate to severe hot flashes due to menopause.

"The approval of Bijuva represents an important, novel and effective treatment option for women," Liu said.

The FDA approved Bijuva's higher dosage of 1 milligram of estradiol and 100 milligrams of progesterone. TherapeuticsMD had also proposed a capsule with a lower dose of estradiol. The FDA "thought there was no reason for a lower dose," the company said.

In August, TherapeuticsMD began distributing Imvexxy, its new treatment for menopausal women who experience painful sex due to vaginal atrophy. Imvexxy was approved for marketing by the FDA in May.

Explore further

Painful sex? New treatment for menopausal women on its way to pharmacies

©2018 Sun Sentinel (Fort Lauderdale, Fla.)
Distributed by Tribune Content Agency, LLC.

Citation: FDA approves pill for hot flashes in menopausal women (2018, October 30) retrieved 7 July 2020 from https://medicalxpress.com/news/2018-10-fda-pill-hot-menopausal-women.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments